IL-21 alleviates allergic asthma in DOCK8-knockout mice

Area of Science:

• Immunology
• Allergy and Asthma Research

Background:

• DOCK8 deficiency is linked to increased risk of allergic diseases, including asthma.
• Understanding the pathogenesis of asthma in DOCK8-deficient individuals is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the mechanisms underlying asthma development in DOCK8-deficient patients.
• To evaluate the therapeutic potential of rmIL-21 in a mouse model of DOCK8-deficiency-associated allergic asthma.

Main Methods:

• Developed a mouse model of allergic asthma using DOCK8-knockout (KO) mice sensitized and challenged with ovalbumin (OVA).
• Assessed airway hyperresponsiveness, inflammatory cell infiltration in the airways, serum IgE levels, and OVA-specific IgE.
• Administered recombinant mouse interleukin-21 (rmIL-21) intranasally to evaluate its therapeutic effects.

Main Results:

• DOCK8-KO mice exhibited heightened airway hyperresponsiveness and significant infiltration of inflammatory cells, particularly eosinophils, in the airways compared to wild-type mice.
• KO mice displayed elevated serum IgE and OVA-specific IgE levels, along with an increase in IgE-producing B cells in blood and spleen.
• Nasal administration of rmIL-21 markedly reduced airway hyperresponsiveness, inflammatory cell infiltration, serum IgE, and IgE-producing B cells.

Conclusions:

• DOCK8-knockout mice are highly susceptible to low-dose OVA-induced allergic airway inflammation and hyperresponsiveness.
• Intranasal administration of rmIL-21 effectively alleviates allergic asthma symptoms in this DOCK8-deficiency mouse model, highlighting its therapeutic potential.